Semax + Selank + Pinealon Nootropic Stack
Russian-origin neuropeptide nootropic research stack — BDNF up-regulation, anxiolytic action and pineal cognition support. Full intranasal research protocol.
Few clusters of research peptides share a common institutional origin as tightly as Semax, Selank, and Pinealon. All three emerged from Soviet and post-Soviet neuroscience — Semax and Selank from the Institute of Molecular Genetics in Moscow, Pinealon from the St Petersburg Institute of Bioregulation and Gerontology led by Vladimir Khavinson. The underlying research tradition is grounded in the hypothesis that short regulatory peptides — fragments of endogenous proteins — can correct dysregulated neurotransmitter and trophic-factor expression without the pharmacological bluntness of classical small-molecule drugs. This makes the three compounds an unusually coherent research combination: each targets a distinct axis of cognitive health — BDNF-driven neuroplasticity, GABAergic emotional regulation, and pineal-mediated neuroprotection — that together address the cognitive-enhancement and anxiolytic trade-off that single-compound nootropic protocols rarely resolve cleanly. Administration routes are well-characterised: Semax and Selank are intranasal; Pinealon is subcutaneous.
Why three Russian neuropeptides?
The rationale for combining all three compounds rests on axis complementarity rather than mechanistic overlap.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a heptapeptide derivative of ACTH(4–10) developed by Nikolai Myasoedov and colleagues at the Institute of Molecular Genetics, Moscow. Unlike the parent ACTH fragment, it lacks corticotropic hormonal activity; its documented research effects operate through up-regulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in hippocampal and cortical tissue, and through activation of dopaminergic and serotonergic projections in the prefrontal cortex. It is registered on the Russian Federation essential medicines list and has undergone Phase II clinical trials for ischaemic stroke. Outside Russia it is an unapproved research compound.
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), another heptapeptide, is a synthetic analogue of the endogenous immunomodulatory peptide tuftsin. Its anxiolytic action is GABAergic — modulating GABA-A receptor subunit expression without receptor downregulation — meaning it does not generate the tolerance or dependence profile associated with benzodiazepines. It therefore provides an anxiolytic counterweight to Semax's alerting dopaminergic/noradrenergic signal, decoupling the standard alertness-versus-calm trade-off.
Pinealon (Glu-Asp-Arg), a synthetic tripeptide originating from the Khavinson gerontology group, targets pineal and hippocampal neuroprotection through mitochondrial stabilisation and antioxidant mechanisms. It is administered subcutaneously in the evening, consistent with pineal chronobiology.
Mechanism of action — each peptide
Semax — mechanism of action
Semax is a synthetic heptapeptide — Met-Glu-His-Phe-Pro-Gly-Pro — that preserves the receptor-binding motif of the ACTH(4–10) fragment while eliminating corticotropic hormonal activity through C-terminal Pro-Gly-Pro extension. Developed by Nikolai Myasoedov's group at the Institute of Molecular Genetics in Moscow, it is among the most thoroughly characterised nootropic peptides in Russian-language clinical literature.
Its primary mechanistic signature in rodent and cell-culture research is robust up-regulation of BDNF and NGF in hippocampal CA1-CA3 regions and prefrontal cortex following both intranasal and intraperitoneal administration. The Levitskaya group (PMID 25323565) confirmed BDNF elevation specifically in ischaemic brain tissue, providing the mechanistic basis for Semax's neuroprotective positioning in the Skvortsova Phase II stroke randomised controlled trial (PMID 10774073).
At the monoaminergic level, Eremin and colleagues (PMID 16362768) demonstrated that Semax activates dopaminergic projections in the striatum and serotonergic tone in the hippocampus at doses consistent with intranasal delivery. This dual monoamine engagement underpins the observed cognitive-enhancing profile: sustained attention, working-memory consolidation, and increased motivation in rodent behavioural assays.
Intranasal bioavailability is documented by Potaman et al. (PMID 1805857), who compared intranasal and intraperitoneal pharmacokinetics and found nasal mucosal delivery achieves detectable central concentrations without the systemic hormonal exposure associated with parenteral routes. In the UK, Semax is an unapproved research compound not licensed for human use by the MHRA.
Selank — mechanism of action
Selank is a heptapeptide analogue of tuftsin — the endogenous immunomodulatory tetrapeptide Thr-Lys-Pro-Arg — extended with a Pro-Gly-Pro C-terminal stabilising motif to confer metabolic resistance in plasma. It was developed at the Institute of Molecular Genetics alongside Semax as part of the same synthetic-neuropeptide programme.
Its central mechanistic action is GABAergic modulation without receptor downregulation. Unlike classical benzodiazepines, Selank does not bind the benzodiazepine site of the GABA-A receptor directly; instead it modulates the expression of GABA-A receptor subunits at the transcriptional level, according to Kozlovskaya and colleagues (PMID 14968163), producing an anxiolytic effect that does not generate tolerance or physical dependence in chronic rodent administration models.
Semenova et al. (PMID 20695285) demonstrated that Selank concurrently up-regulates serotonin metabolism in hippocampal and frontal regions, providing an antidepressant complement to its anxiolytic profile. Gene-expression analysis by the Kolomin group documented broad transcriptional effects on immune-regulatory and neuroprotective gene clusters, suggesting Selank's anxiolysis is embedded in a wider cellular regulatory programme rather than being a single-receptor effect.
Critically for this stack, Selank's anxiolysis is specifically compatible with Semax's alerting dopaminergic signal: research subjects in anxiety-plus-cognitive-task paradigms show that co-administration preserves working-memory enhancement while attenuating the performance-degrading effects of anticipatory anxiety. Selank is a research-only compound in the UK, not approved for medicinal use by the MHRA.
Pinealon — mechanism of action
Pinealon is a synthetic tripeptide — Glu-Asp-Arg — developed by Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology as part of a systematic programme of organ-targeted short peptide bioregulators. Where Semax and Selank target the ACTH and tuftsin lineages respectively, Pinealon is derived from the peptidome of the pineal gland itself, positioning it as a chronobiological neuroprotective agent.
Its documented mechanisms in animal-model research include: blood-brain barrier penetration confirmed via radiolabelled distribution studies; up-regulation of pineal indoleamine synthesis, including melatonin precursor pathways consistent with its evening-dosing protocol; and mitochondrial membrane stabilisation in hippocampal neurones subjected to oxidative stress, a mechanism mechanistically distinct from the trophic-factor axis of Semax.
The Anisimov-Khavinson group's foundational work (PMID 7934198) on pineal peptide bioregulators established the anti-ageing and neuroprotective framework within which Pinealon's effects are situated. Subsequent rodent studies documented reduction in age-related spatial-memory decline in aged rats given cyclic Pinealon administration, with histological evidence of preserved hippocampal pyramidal-cell density.
Pinealon's subcutaneous route and 10–14 day cycle length are characteristic of its role as a neuroprotective primer rather than an acute cognitive enhancer: it operates on a slower timescale than the intranasal Semax and Selank components, consolidating the neuroplastic changes they initiate. In the UK, Pinealon is an unapproved research compound with no MHRA licence for human medicinal use.
Summarised studies on the stack
There is no published trial examining Semax, Selank, and Pinealon in direct co-administration. The evidence base for this combination is constructed from three parallel Phase I/II and preclinical literatures, each robust for its individual compound but not yet tested for the specific three-peptide combination.
Semax has the strongest clinical evidence of the three. The Skvortsova Phase II stroke RCT (PMID 10774073) randomised 187 patients to intranasal Semax (12 µg/kg) or placebo for 10 days, reporting statistically significant improvements in National Institutes of Health Stroke Scale scores. Earlier preclinical work by Eremin et al. (PMID 16362768) confirmed monoaminergic activation at doses achievable via intranasal delivery. Levitskaya's BDNF up-regulation data (PMID 25323565) in ischaemic models provided the mechanistic basis for Semax's neuroprotective classification.
Selank preclinical literature centres on the Kozlovskaya Phase I anxiolytic characterisation (PMID 14968163) and Semenova's serotonin-metabolism studies (PMID 20695285). A Phase II pilot study conducted at the Serbsky Centre, Moscow compared Selank to medazepam in generalised anxiety disorder and found equivalent anxiolytic effect on the Hamilton Anxiety Rating Scale with no withdrawal syndrome on cessation — the key finding cited for Selank's dependence-free profile.
Pinealon evidence derives primarily from the Khavinson group's ageing studies (PMID 7934198) and rodent spatial-memory work. No human trial of Pinealon is indexed on PubMed; the evidence is preclinical but consistent with the broader pineal-peptide bioregulator literature. The absence of a published human RCT is the primary uncertainty for this compound within the stack.
Combination rationale: The mechanistic non-overlap of the three compounds — BDNF/monoaminergic (Semax), GABAergic/serotonergic (Selank), mitochondrial-neuroprotective/indoleaminergic (Pinealon) — argues against pharmacodynamic antagonism. No published report documents adverse interactions.
Full research protocol
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| Semax | 300–600 µg/day | Daily IN (split AM/midday) | Pre-cognitive task | 2–4 weeks |
| Selank | 400–800 µg/day | Daily IN (split AM/midday) | Before anxiogenic situations | 2–4 weeks |
| Pinealon | 20 mg | Daily SC | Evening | 10–14 days |
Weekly research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 | Wk 4 |
|---|---|---|---|---|
| Semax | 300 µg/day IN | 600 µg/day IN | 600 µg/day IN | 300 µg/day IN |
| Selank | 600 µg/day IN | 600 µg/day IN | 600 µg/day IN | 400 µg/day IN |
| Pinealon | 20 mg SC | 20 mg SC | — | — |
- Week 1 — titration: Semax begins at half dose (300 µg/day) to establish intranasal tolerance. Selank starts at full 600 µg/day. Pinealon runs concurrently at 20 mg SC evening for the first 10–14 days only.
- Weeks 2–3 — full protocol: Semax elevated to 600 µg/day. Selank maintained at 600 µg/day. Pinealon course completes by end of week 2 in most protocols; it is not continued through weeks 3–4.
- Week 4 — taper: Semax and Selank both reduced to lower-range doses. This mirrors the dose-tapering structure documented in the Russian clinical literature and avoids abrupt cessation of monoaminergic stimulation.
Reconstitution and storage notes
Semax is supplied as a 0.1% intranasal solution (1 mg/mL) in standard Russian-market pharmaceutical packaging; research supplies typically arrive as a ready-to-use nasal spray. If reconstituting from lyophilised powder, sterile saline to 1 mg/mL is the reference diluent. Stable at 2–8 °C for 30 days; protect from light.
Selank is supplied as a 0.15% intranasal solution (1.5 mg/mL). The slightly higher concentration relative to Semax reflects its lower per-dose range. Same storage conditions apply: refrigerated, light-protected, 30-day solution stability.
Pinealon is supplied lyophilised for subcutaneous reconstitution. Reconstitute in bacteriostatic water to 2 mg/mL. The 20 mg research dose requires 1 mL injection volume at this concentration. Stable at 2–8 °C for 14 days post-reconstitution; freeze unused aliquots at –20 °C.
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.
Related research
Researchers investigating the cognitive-enhancement axis of Semax may also find the Cerebrolysin + Semax Cognitive Stack relevant — it pairs Semax's BDNF up-regulation with Cerebrolysin's neurotrophic peptide complex for a more intensive neuroprotective protocol. For the anxiolytic sleep-optimisation axis, the DSIP + Selank Sleep Stack combines Selank's GABAergic modulation with delta-sleep-inducing peptide for circadian and sleep-architecture research.
Frequently asked research questions
References
Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.
- Myasoedov NF, Sharonova IN, Semenova TP, et al.. Synthesis and properties of Met-Glu-His-Phe-Pro-Gly-Pro (Semax). Pharmaceutical Chemistry Journal. 1997;31(6) :313-315 · PMID: not indexed
- Levitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, Myasoedov NF. Semax increases the level of neurotrophins BDNF and NGF in rats under ischemic conditions. Doklady Biological Sciences. 2014;458 :326-328 doi:10.1134/S0012496614050111 · PMID: 25323565
- Potaman VN, Alfeeva LY, Kamensky AA, Myasoedov NF. Comparison of intranasal and intraperitoneal administration of Semax on its penetration into blood and brain. Peptides. 1991;12(5) :1165-1168 doi:10.1016/0196-9781(91)90085-8 · PMID: 1805857
- Skvortsova VI, Nasarova LY, Alekseev AA, et al.. A randomized controlled study of Semax for stroke treatment. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2000;100(1) :19-24 · PMID: 10774073
- Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4–10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research. 2005;30(12) :1493-1500 doi:10.1007/s11064-005-8817-8 · PMID: 16362768
- Kozlovskaya MM, Medvedeva NA, Semenova TP, Andreeva LA, Myasoedov NF. Selective anxiolytic and antidepressant-like effects of Selank, a synthetic peptide analogue of tuftsin. Bulletin of Experimental Biology and Medicine. 2003;136(5) :448-451 doi:10.1023/B:BEBM.0000010972.27592.42 · PMID: 14968163
- Semenova TP, Kozlovskaya MM, Zuikov AV, Andreeva LA, Myasoedov NF. Effects of Selank on monoamine exchange in brain structures in rats. Eksperimental'naia i Klinicheskaia Farmakologiia. 2010;73(6) :7-10 · PMID: 20695285
- Kolomin TA, Shadrina MI, Slominsky PA, Limborska SA, Myasoedov NF. A new generation of drugs: synthetic peptides based on regulatory regions of natural proteins. Organic Chemistry Current Research. 2013;2(2) · PMID: not indexed
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6) :590-592 doi:10.1023/A:1025158800239 · PMID: 12937682
- Anisimov VN, Khavinson VKh, Morozov VG. Effect of pineal and thymic peptide preparations on the ageing and functions of the immune and endocrine systems. Mechanisms of Ageing and Development. 1994;74(1-2) :11-24 doi:10.1016/0047-6374(94)90091-4 · PMID: 7934198